INDV vs PGNY: fair value comparison
Indivior Pharmaceuticals, Inc. and Progyny, Inc. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, PGNY currently sits closer to the top of our ranking by discount to fair value. PGNY carries the stronger quality grade.
| INDV | PGNY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $32.45 | $26.86 |
| 12-month range | $24.78–$41.83 | $16.30–$32.36 |
| Rank by discount to fair value | #17 of 108 Healthcare | #16 of 108 Healthcare |
| Quality grade | F | A |
| Leverage | Low | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Uptrend |
| DCF cross-check | — | Undervalued |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: INDV fair value analysis · PGNY fair value analysis